Preprint · OA
via OpenAlex
A role for alpha-synuclein in the regulation of dopamine biosynthesis.
Ruth G. Perez, Jack C. Waymire, Eva Lin, Jen J. Liu, Fengli Guo, Michael J. Zigmond
PubMed · 2002 · ▲ 632 citations
Abstract
The alpha-synuclein gene is implicated in the pathogenesis of Parkinson's disease. Although alpha-synuclein function is uncertain, the protein has homology to the chaperone molecule 14-3-3. In addition, alpha-synuclein can bind to 14-3-3, and both alpha-synuclein and 14-3-3 bind to many of the same proteins. Because 14-3-3 binds to and activates tyrosine hydroxylase, the rate-limiting enzyme in dopamine (DA) biosynthesis, we explored whether alpha-synuclein also bound to tyrosine hydroxylase and influenced its activity. Immunoprecipitation revealed an interaction between alpha-synuclein and tyrosine hydroxylase in brain homogenates and MN9D dopaminergic cells. Colocalization of alpha-synuclein with tyrosine hydroxylase was confirmed by immunoelectron microscopy. To explore the consequences of the interaction, we measured the effect of recombinant alpha-synuclein on tyrosine hydroxylase activity in a cell-free system and observed a dose-dependent inhibition of tyrosine hydroxylase by alpha-synuclein. To measure the impact of alpha-synuclein on tyrosine hydroxylase in dopaminergic cells, we stably transfected MN9D cells with wild-type or A53T mutant alpha-synuclein. Overexpression of wild-type or A53T mutant alpha-synuclein did not significantly alter tyrosine hydroxylase protein levels in our stably transfected cells. However, overexpressing cell lines had significantly reduced tyrosine hydroxylase activity and a corresponding reduction in dopamine synthesis. The reduction in cellular dopamine levels was not caused by increased dopamine catabolism or dopamine efflux. These data suggest that alpha-synuclein plays a role in the regulation of dopamine biosynthesis, acting to reduce the activity of tyrosine hydroxylase. If so, a loss of soluble alpha-synuclein, by reduced expression or aggregation, could increase dopamine synthesis with an accompanying increase in reactive dopamine metabolites.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1523/jneurosci.22-08-03090.2002
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F., & Zigmond, M.J. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. <em>PubMed</em>. https://doi.org/10.1523/jneurosci.22-08-03090.2002
Vancouver
Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for alpha-synuclein in the regulation of dopamine biosynthesis. PubMed. 2002. doi:10.1523/jneurosci.22-08-03090.2002.
BibTeX
@unpublished{ruth2002Arolef,
title = {A role for alpha-synuclein in the regulation of dopamine biosynthesis.},
author = {Ruth G. Perez and Jack C. Waymire and Eva Lin and Jen J. Liu and Fengli Guo and Michael J. Zigmond},
journal = {PubMed},
year = {2002},
doi = {10.1523/jneurosci.22-08-03090.2002},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · CC-BY
Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease
Biogerontology 2024
Open access · CC-BY
Inhibition of mTOR prevents glucotoxicity-mediated increase of SA-beta-gal, p16INK4a, and insulin hypersecretion, without restoring electrical features of mouse pancreatic islets
The Journal of Immunology 1995
Citation only
Activation of telomerase in human lymphocytes and hematopoietic progenitor cells
Research Square 2020
Preprint · CC-BY
Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity
Aging Cell 2019
Open access · CC-BY
Downregulation of the inflammatory network in senescent fibroblasts and aging tissues of the long‐lived and cancer‐resistant subterranean wild rodent, Spalax
Biomedicines 2024
Open access · CC-BY